Name: MRT-2359

Cat#: EX-A7775

Chemical Structure of MRT-2359:



Chemical Name	(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)methyl (2-fluoro-5-(trifluoromethoxy)phenyl)carbamate

Molecular Weight	495.38	Storage	2 years -20°C powder 6 months -80°C in solvent Away from light
Formula	$C_{22}H_{17}F_4N_3O_6$		
CAS No.	2803881-11-8	Synonyms	MRT 2359; MRT2359

Target: Others
Pathway: Others
Research Areas: Cancer

Solubility (25°C) *	In vitro	DMSO	Soluble
		Ethanol	N/A
		Water	N/A
	In vivo （should be freshly prepared each time）		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	2.0187mL	10.0933mL	20.1865mL
5 mM	0.4037mL	2.0187mL	4.0373mL
10 mM	0.2019mL	1.0093mL	2.0187mL

*The above data is based on the product molecular weight 495.38.

Biological Activities:

Description	MRT-2359 is an orally active and potent degrader of GSPT1 with anti-tumor activity. MRT-2359 also inhibits the growth of esistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells. MRT-2359 exhibits preferential activity in MYC-driven cell lines, such as N- and L-MYC high NSCLC and SCLC patient-derived xenografts (PDXs)[1]. .

References	[1]. Gavory G, et al. Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction[J]. Cancer Research, 2023, 83(7_Supplement): 3449-3449.